Hyloris announces FDA acceptance of new drug application for Maxigesic IV in post-operative pain

Latest pharma news update

Hyloris Pharmaceuticals SA, a speciality biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Maxigesic IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain. In addition, the Company informs that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance and granted the process and formulation patents of Maxigesic IV in the U.S. The patents are expected to be issued early 2022 after completion of the final administrative requirements.1

The FDA is expected to confirm the Prescription Drug User Fee Act (PDUFA) action date for the filing in due course. The PDUFA date – the date at which the FDA must respond to the application – will be notified later this year and is estimated to be between August and September 2022.

Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “The NDA acceptance marks an important milestone for our company, and is a major step toward bringing much needed innovation in non-opioid, post-operative pain management and addressing the current opioid crisis, which is responsible for many deaths in the U.S. each year. Together with our partners, we are looking forward to working with the FDA and to further executing on our global commercial rollout. Upon approval, Maxigesic IV will be commercialised by Hikma Pharmaceuticals, a leading supplier of complex, injectable hospital products in the U.S.”

The NDA submission is based on positive data from two Phase 3 studies of Maxigesic IV: i) a randomised, double-blind, placebo-controlled efficacy trial in 276 patients following bunionectomy surgery; and ii) an open-label, multi-centre, single arm, multiple dose safety study in 232 patients undergoing general, orthopaedic, or plastic surgery. As previously reported, treatment with Maxigesic IV was well-tolerated, had a faster onset of action and offered higher pain relief compared to ibuprofen IV or paracetamol IV alone in the same doses. Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of secondary endpoints, including reduced opioid usage rates compared to the paracetamol IV, ibuprofen IV and placebo treatment groups (P<0.005).2 The open-label Phase 3 safety study demonstrated that Maxigesic IV, administered 6-hourly as a 15-minute infusion over an exposure period of 48 hours to 5 days, was safe and well-tolerated, and was perceived positively by study participants, supporting a favourable risk benefit profile.3

Maxigesic IV has been developed under the collaboration agreement signed in 2012 between Hyloris and AFT Pharmaceuticals. The product is currently licensed in over 100 countries across the globe, has been registered in 28 countries and is now launched in 5 countries. Maxigesic IV is protected by several granted patents and pending patent applications.

About Post-Operative Pain Management
Globally, approximately 1.2 billion vials are sold per year in the non-opioid IV analgesic space, of which >260 million vials of IV paracetamol represent a global market of >$700 million.4 In 2019, 51 million surgical procedures were performed in the U.S. and the overall treatment of post-operative pain has not substantially improved over the past 20 years, with the misuse of opioids remaining a key public health issue. Recently released data by the Centers for Disease Control and Prevention (CDC) show that drug overdose deaths reached a record high of 93,331 in 2020, of which 57,550 (62%) were due to synthetic opioid misuse. This represented a significant increase as compared to 2015 where synthetic opioids were involved in 18% of all overdose deaths. The CDC estimate that the total economic burden of prescription opioid misuse in the U.S. alone is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.

Tags : #Maxigesiciv #Painkillers #Opoids #FDA #FDAAcceptance #LatestPharmaNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-


Trending Now

CDSCO has approved Boehringer Ingelheim's Jardiance for the treatment of heart failure.May 20, 2022
Hanuman raises over $.5 million to expand its emergency medical response services in Bihar, Jharkand and UP May 20, 2022
Sudden Infant Death Syndrome (SIDS) – Causes and preventive methodsMay 20, 2022
Healthcare Innovation Challenge: Data's Expanding Role in the Healthcare SectorMay 20, 2022
Homeopathy in Pregnancy - Homeopathy Treatment | MedicircleMay 20, 2022
MetroMedi launches the MetroMedi Relief platform for mental and sexual health wellbeing.May 20, 2022
Top Health Benefits for Butter milk May 20, 2022
Sumit Agarwal- Born with Cerabral Palsy to today being an acclaimed entrepreneur in the public relations industry in IndiaMay 20, 2022
Five eye hospitals in the Tri-city region have been acquired by Dr. Agarwal's Eye Hospital.May 19, 2022
World Family Doctor Day, 2022 – Family doctor makes care easily accessible May 19, 2022
Adani Enterprises will explore the healthcare industry.May 19, 2022
Tips for Weight Loss May 19, 2022
What should be the diet during menopause? May 19, 2022
5 Tips To Get Rid Of Cracked Heels In SummerMay 19, 2022
How is meditation beneficial in reducing low blood pressure?May 18, 2022
Why should we not eat mushrooms because of kidney disease? May 18, 2022
Zinc Deficiency Symptoms in the BodyMay 18, 2022
Dawaa Dost : Making drugs more accessible and affordable.May 18, 2022
Control and Manage HIV with ART therapy - MedicircleMay 18, 2022
Top 5 Solutions for Hair Detox May 17, 2022